Author David Lane, COO, eProfiler Solutions Ltd. May 2022.

eProfiler Solutions Ltd was awarded Silver in the Medical Category for innovation at ITEX 2022. Per the previous blog post, eProfiler Solutions attended this event to launch its eProfiler L solution and winning this award was a bonus to the team.

Most innovations at ITEX 2022 are for innovative applications of existing science - typically specific industry applications. As a result, the fundamental scientific innovation behind eProfiler Solutions was not a big factor in how the solution was judged. eProfiler will seek out other events that give more weight to fundamental innovation.

Find out more at eProfilerSolutions.com where you can also contact us. Or you can email Info@eProfilerSolutions.com to contact the eProfiler team.

This post was written by David Lane one of the founders and the Chief Operating Officer of eProfiler Solutions Ltd. eProfiler Solutions has exclusive rights to patented technology invented by its founder Dr. Vengadesh Periasamy and licensed from the University of Malaya. David can be reached at David@eProfilerSolutions.com.

Author David Lane, COO, eProfiler Solutions Ltd. May 2022.

The eProfiler team attended ITEX 2022 in Kuala Lumpur at the KLCC (KL Convention Centre), stand 2Q174. We presented for the first time the eProfiler-L solution. This showed the end-to-end flow of:

• individual (single use) sensor placed into the cartridge compartment of the eProfiler-L2 Device

• a pipette with a stem cell sample was used to place a 10ml droplet on the sensor and left to settle for 4 minutes

• the Tester APP running on a PC linked via a USB cable to the eProfiler-L device was use to setup the test, record details about the test sample and to trigger the test

• the results of the test were uploaded to the eProfiler Analytics Cloud and available immediately

• the test result could be adjusted by (1) cancelling specific replicates and/or (2) adjusting for the impact of the solution by subtracting a Blank

• the test result was compared to other test results and to existing eProfiles - demonstrating the ability to evaluate a sample's equivalence with other samples and matching against a know eProfile

• the test result was added to an existing eProfile

The demonstrations were performed without any problems, demonstrating the stability of the solution and its readiness to be deployed commercially to customers (with a focus on revenue) and R&D Partners (with a focus on developing eProfiles and publishing research to validate the solution and eProfiles created)

This is a major milestone for eProfiler Solutions Ltd as the company has now (1) taken a new raw science, (2) turned this into a product, validating the potential of the science, and (3) as demonstrated at ITEX 2022 turned this product into a solution that can scale globally.

The eProfiler Solutions founders would like to than its strategic partners, and in particular Zynix Original and Lajward, for their support in making this happen.

Find out more at eProfilerSolutions.com where you can also contact us. Or you can email Info@eProfilerSolutions.com to contact the eProfiler team.

This post was written by David Lane one of the founders and the Chief Operating Officer of eProfiler Solutions Ltd. eProfiler Solutions has exclusive rights to patented technology invented by its founder Dr. Vengadesh Periasamy and licensed from the University of Malaya. David can be reached at David@eProfilerSolutions.com.

Author David Lane, COO, eProfiler Solutions Ltd. February 2021.

Given the debate and costs associated with future pandemic preparedness, we need to ask the question - are further pandemics likely to occur?

Leaving aside conspiracy theories and the development of biological weapons, one simple fact means that the world will see future pandemics - we share this planet with animals. Animals provide us with many benefits. Growing up on a farm I experienced first hand how many people work with and/or interact with animals daily. Animals provide food, livelihoods, sport, companionship and more for people across the world.

Animals carry harmful germs and sometimes these can spread to humans and cause illness - these are known as zoonotic diseases. Zoonotic diseases are caused by harmful pathogens/germs like viruses, bacteria, parasites and fungi. Animals carrying these pathogens can often appear healthy despite the same pathogen leaving humans sick or dead.

Looking back historically, many of today’s human diseases are caused by microbes whose ancestors came from animals first domesticated by early humans. Biologists believe that the measles virus stemmed from canine distemper and rinderpest, an affliction of cattle; that rhinoviruses, agents of the common cold, came to us from horses; and that smallpox is a close cousin of cowpox. Of the more than 1,700 known viruses, bacteria, and other pathogens that infect people, more than half either originated in or now come directly from animals -- the rest come from the environment around us, such as soil, water, and air. And of the 37 new infectious diseases identified in the past 30 years, more than two-thirds came to us from animals. COVID-19 likely jumped species in this way - and the next deadly pandemic to sweep the world could also jump species in this way.

Severe Acute Respiratory Syndrome (SARS) is a recent example of this. In the spring of 2003 this new and deadly viral illness swept out from China’s Guangdong Province and spread rapidly around the world before it was contained that summer. SARS originated in Chinese horseshoe bats, animals that are used for food and medicine in many parts of Asia, and was then “amplified” through the infection of civet cats, a step leading to a mutation that makes the disease transmissible to humans. The virus infected 8,098 people, of which 774 died—a nearly 10 percent mortality rate.

Leptospirosis (a bacterial disease spread through the urine of infected animals or through soil or water contaminated by infected urine) can cause a wide range of symptoms in humans, including high fever, vomiting, and even meningitis and liver failure.

A handful of deadly infectious diseases claim millions of lives worldwide each year: (1) lower respiratory tract infections, ~6,500k/yr (2) diarrheal diseases, ~1,600k/yr (3) HIV/AIDS, tuberculosis, ~2,000k/yr (4) malaria ~400k/yr deaths, and most recently (5) COVID-19 ~1,000k/yr. Together, they account for nearly one-fifth of deaths globally. Several of these diseases have plagued humankind throughout history, often decimating populations with greater efficiency than wars. Despite advances in vaccines, antibiotics, et al, these diseases continue to kill, particularly in the developing world and its children - highlighting the implications of non-equitable access to affordable, effective health care in poorer parts of the world.

Scientist estimate that potentially 60% of know human diseases can be spread by animals - and 75% of new or emerging infectious diseases in people come from animals.

The main mechanisms for spreading pathogens between animals and people are (1) direct contact with the body fluids, eg saliva, blood, urine, mucous, feces of an infected animal, (2) indirect contact via common surfaces and habits, (3) bites, eg tick, mosquito or flea, (4) food, eg eating/drinking raw milk or undercooked meat and eggs or poorly cleaned raw vegetables - contaminated by an infected animal, and (4) water via drinking or contact with water that has been contaminated by an infected animal.

Imagine if we had universal, accurate and low-cost diagnosis solutions that could identify today’s known diseases in humans, animals, water, and plants. Imagine if, in the course of testing for known diseases, these diagnosis systems could capture new zoonotic diseases and their rate of spread and mutation? Once a new zoonotic disease or mutation is identified, all prior tests results could be revisited and the origin and spread understood.

This is the promise of eProfiler Solutions Ltd. eProfiler uses digital testing techniques based on physics applied to biology. It is one to two orders of magnitude cheaper, faster and more accurate than current testing. It can look for multiple diseases in one test. It can record results for as yet unidentified diseases and mutations that are then used to isolate what is new and to then retrospectively match prior test results to these new diseases and mutations once identified.

eProfiler provides a radical and transformative solution to one of the most urgent and economically compelling challenges of our time.

Find out more at eProfilerSolutions.com where you can also contact us. Or you can email Info@eProfilerSolutions.com to contact the eProfiler team.

This post was written by David Lane one of the founders and the Chief Operating Officer of eProfiler Solutions Ltd. eProfiler Solutions has exclusive rights to patented technology invented by its founder Dr. Vengadesh Periasamy and licensed from the University of Malaya. David can be reached at David@eProfilerSolutions.com.

Author David Lane, COO, eProfiler Solutions Ltd. December 2020.

Despite many disease outbreaks, reports and recommendations over the last two decades calling for pandemic preparedness, the world was not ready for COVID-19. COVID-19 was not the first pandemic and more will follow. Many pandemics in the past, such as Spanish Flu in 1918, have been far more deadly than COVID-19 with vastly higher mortality rates.

We cannot afford to simply move on and forget the catastrophe that has been COVID-19 - all too often governments fail to follow through due to the distraction of other immediate concerns. We - governments, employers and individuals - need to prepare for the next pandemic in ways that include all in society and balance the need for health with broader needs. COVID’s disruption to broader health systems and economies is damaging and shortening lives in many ways beyond the direct and immediate impacts of the disease.

A report by the Global Preparedness and Monitoring Board puts the cost of this COVID pandemic at over US$11 trillion and counting.

Future preparedness makes economic sense. This preparedness will need collaboration between countries, governments and the private sector -- and must operate at the community level. The elephant in the room here is the core issue of ‘affordable health care’ - low cost, affordable, and available prevention (if possible), management (essential and arguably something we can control) and cure (if possible/eventually).

Governments, the WHO, the UN and others are all making appropriate noises about this need for future preparedness. But what does this actually mean? What is it that we need?

Better testing is the starting point. Available, accurate, affordable testing with near-immediate results. But, this testing must be able to identify new diseases that we do not know about yet and immediately monitor their spread and mutation - not simply check for what we know about.

This is a challenge, particularly with the current testing technologies such as PCR (Polymerase Chain Reaction) and immunoassays. These technologies enable us to react (albeit slowly and expensively) but not to anticipate. They are inherently slow to deploy, slow to test and inaccurate. There is plenty of literature available on the challenges of current testing regimes which we can cover in a separate blog.

The world needs new technologies and a new approach to testing. The report by the Global Preparedness and Monitoring Board suggests the need for:

“identifying, predicting and detecting the emergence of pathogens with pandemic potential based on a ‘One Health’ approach that integrates animal and human health building core public health capacities and workforce for surveillance, early detection and sharing of information on outbreaks and similar events”

Imagine if we had universal, accurate and low-cost diagnosis solutions that could identify today’s known diseases in humans, animals, water, and plants. Imagine if, in the course of testing for known diseases, these diagnosis systems could capture new diseases and their rate of spread and mutation? Once a new disease or mutation is identified, all prior tests results could be revisited and the origin and spread understood.

This is the promise of eProfiler Solutions Ltd. eProfiler uses digital testing techniques based on physics applied to biology. It is one to two orders of magnitude cheaper, faster and more accurate than current testing. It can look for multiple diseases in one test. It can record results for as yet unidentified diseases and mutations that are then used to isolate what is new and to then retrospectively match prior test results to these new diseases and mutations once identified.

eProfiler’s central cloud services platform will provide a global resource for tracking and sharing the early identification and spread of any disease identified in its library of disease eProfiles - with support for retrospective re-analysis of test results as new disease eProfiles are identified. This test database applies to tests of humans, animals, water and plants - enabling pathogens to be tracked more broadly that simply their human hosts.

If all travel, event venues, employee building access relied on eProfiler’s low cost, accurate and near-immediate testing results to protect the health of customers and employers from know diseases, the infrastructure would be in place to keep the world safe and moving in the face of known diseases - and significantly lower current health care costs everywhere with low-cost prevention and early identification. However, this same infrastructure, at no additional cost would be able to identify and track the emergence of new pathogens with pandemic potential.

eProfiler provides a radical and transformative solution to one of the most urgent and economically compelling challenges of our time.

Find out more at eProfilerSolutions.com where you can also contact us. Or you can email Info@eProfilerSolutions.com to contact the eProfiler team.

This post was written by David Lane one of the founders and the Chief Operating Officer of eProfiler Solutions. eProfiler Solutions has exclusive rights to patented technology invented by its founder Dr. Vengadesh Periasamy and licensed from the University of Malaya. David can be reached at David@eProfilerSolutions.com.